@article{Bousquet_J-2020_26820,
title = {Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement},
author = {Bousquet, J. and Akdis, C. and Bachert, C. and Klimek, L. and Ansotegui, I. and Bedbrook, A. and Bosnic-Anticevich, S. and Canonica, G. and Chivato, T. and Cruz, A. and Czarlewski, W. and Del Giacco, S. and Du, H. and Fonseca, J. and Gao, Y. and Haahtela, T. and Hoffmann‐Sommergruber, K. and Ivancevich, J. and Khaltaev, N. and Knol, E. and Kuna, P. and Larenas-Linnemann, D. and Mullol, J. and Naclerio, R. and Ohta, K. and Okamoto, Y. and O'Mahony, L. and Onorato, G. and Papadopoulos, N. and Pfaar, O. and Samolinski, B. and Schwarze, J. and Toppila-Salmi, S. and Ventura, M. and Valiulis, A. and Yorgancioglu, A. and Zuberbier, T. and Pawankar, R.},
month = {mar},
year = {2020},
abstract = {A novel strain of human coronaviruses, named by the International Committee on Taxonomy of Viruses (ICTV)as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged and caused an infectious disease. This disease has recently been referred to by the World Health Organisation (WHO) as the “coronavirus disease 2019” (COVID-19). Since the first report of this disease in December 2019 in Wuhan, China,COVID-19 has aggressively spread across the globe. WHO declared it a pandemic on March 11.},
pages = {2440-2444},
volume = {75},
issue = {10},
journal = {Allergy},
publisher = {Wiley},
url = {https://doi.org/10.1111/all.14302},
}
